🏛️ Verified NIH Record • Updated 2026-07-05
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs) (NCT07465835)
🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Electra Therapeutics Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1, two-part, multicenter study to evaluate ELA026 in participants ≥18 years old with relapsed/refractory TCM following any line of prior therapy who are eligible for investigational treatments.
Who can join: Review the eligibility criteria below.
Location: Yale New Haven Hospital — New Haven, Connecticut
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- Yale New Haven Hospital — New Haven, Connecticut
- Emory University Hospital — Atlanta, Georgia
- START, Midwest — Grand Rapids, Michigan
- Memorial Sloan Kettering — New York, New York
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- MD Anderson — Houston, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All T Cell Malignancies clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.